What's Going On With Profusa Stock Tuesday?

Benzinga_recent_news04-07

Profusa, Inc. (NASDAQ:PFSA) shares tumbled during Tuesday's trading session. On Monday, Profusa said it signed a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625543499?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-04-07 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625543499","market":"sh","top_or_hot":-1,"title":"What's Going On With Profusa Stock Tuesday?","media":"Benzinga_recent_news","content":"<div>\n<p>Profusa, Inc. (NASDAQ:PFSA) shares tumbled during Tuesday's trading session.\nOn Monday, Profusa said it signed a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform in ...</p>\n\n<a href=\"https://www.benzinga.com/markets/small-cap/26/04/51682850/whats-going-on-with-profusa-stock-tuesday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Profusa Stock Tuesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Profusa Stock Tuesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-07 23:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/small-cap/26/04/51682850/whats-going-on-with-profusa-stock-tuesday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Profusa, Inc. (NASDAQ:PFSA) shares tumbled during Tuesday's trading session.\nOn Monday, Profusa said it signed a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform in ...</p>\n\n<a href=\"https://www.benzinga.com/markets/small-cap/26/04/51682850/whats-going-on-with-profusa-stock-tuesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.benzinga.com/markets/small-cap/26/04/51682850/whats-going-on-with-profusa-stock-tuesday","article_id":"2625543499","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/07/cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/small-cap/26/04/51682850/whats-going-on-with-profusa-stock-tuesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625543499","pubTimestamp":1775574060,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Profusa ($PFSA) shares down 40% to $1.10. Company signs LOI for $30M acquisition to scale its diagnostics and monitoring business.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","PFSA":"Profusa Inc"},"translate_title":"周二Profusa股票发生了什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFSA":1},"content_text":"Profusa, Inc. (NASDAQ:PFSA) shares tumbled during Tuesday's trading session.\nOn Monday, Profusa said it signed a Letter of Intent to acquire BioInsights' PanOmics multi-omics diagnostics platform in an all-equity deal valued at about $30 million, marking its entry into molecular diagnostics.\nThe company said the platform will complement its Lumee real-time biochemistry monitoring system and strengthen its push into precision medicine, including a collaboration with Mayo Clinic focused on pancreatic cancer.\nUnder the proposed terms, Profusa would gain exclusive rights to the platform, while BioInsights would provide clinical samples for validation and receive a 3% royalty on net revenue. The deal is subject to due diligence, shareholder approval, and other customary conditions.\nProfusa said the integration could accelerate the development of lab-developed tests and support a scalable diagnostics and monitoring business. Initial commercialization efforts will target pancreatic cancer, with more than 13,000 annual surgeries in the U.S. and an estimated $26 million market opportunity.\nProfusa is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes across a range of diseases and conditions.\nIts core idea is bioengineered sensors designed to integrate with the body and continuously transmit clinical-grade data for personal and medical use.\nThe company's first offering in the European Union, the Lumee Oxygen Platform, is built to report tissue oxygen levels at different regions of interest, both acutely and long-term.\nIn that context, adding BioInsights' PanOmics platform is meant to broaden Profusa from sensing into multi-omics diagnostics, pairing real-time monitoring with lab-developed tests and clinically annotated samples.\nPFSA Price Action: Profusa shares were down 40.27% at $1.10 at the time of publication on Tuesday, according to Benzinga Pro data.\nPhoto by Aunt Spray via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625543499","isCrawlerRequest":true}